health
Sun Pharma shares jump 7% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
TL;DR
- Sun Pharmaceutical Industries will acquire Organon & Co for $11.75 billion in an all-cash deal.
- The acquisition is expected to make Sun Pharma one of the top 25 global pharmaceutical companies with $12.4 billion in revenue.
- Organon, spun off from Merck in 2021, specializes in women's health and biosimilars.
- The deal aligns with Sun Pharma's strategy to grow its Innovative Medicines business.
- Organon's key markets include the U.S., Europe, China, Canada, and Brazil.
- This is Sun Pharma's sixth acquisition in the last 16 years, following previous deals like Taro Pharma and Ranbaxy Laboratories.